One of the most prevalent and least understood disorders in women is uterine fibroids. Throughout their lives, up to 70% of white women and more than 80% of women of African heritage are diagnosed with these tumors, also known as myomas, which mostly afflict women during their reproductive years. The delivery and expense of healthcare are significantly impacted by this disease on a global scale. Even though the majority of women with fibroids are asymptomatic, about 30% of them will require intervention due to significant symptoms that may include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, frequent urination, constipation, or infertility. Furthermore, poor obstetric outcomes have been linked to fibroids.
The current options for treating symptomatic fibroid include interventional radiology, medicinal, surgical, and expectant care. Surgery is still sometimes necessary, there is no doubt about that, but we must now determine whether using hormonal therapy and SPRMs enables less invasive surgery or even completely avoids surgery. The size, quantity, and position of the fibroids, as well as the gynecologist's experience and the technology that is available, all come into play when deciding between less invasive methods (uterus-sparing choices, like myomectomy). The majority of fibroids management techniques still involve surgical interventions, with hysterectomy, laparoscopic myomectomy, and hysteroscopic myomectomy being the most popular procedures.
For decades, the only procedure available to women who desired to keep their uterus was excision of the fibroids and anatomical restoration of the uterus, also during obstetrics. In between 80 and 90 percent of cases, myomectomy patients have symptom alleviation or symptom reduction. After surgery, the fibroids should not recur but, due to the growth of additional fibroids, up to 33% of women who undergo this surgery will require a second operation within 5 years. Depending on the quantity, size, and location of fibroids, this procedure can be performed in one of three ways. However, surgical options do not always solve the problems, especially in obstetrics.
In this Research Topic, we will try to dissect all the problems of fibroid surgery, both in gynecology and in obstetrics, criticizing many aspects of the topic that have not yet been fully clarified. We expect to receive, but not limited to: original articles, case reports and reviews on the topic of Fibroid Surgery Controversies in Obstetrics and Gynecology.
One of the most prevalent and least understood disorders in women is uterine fibroids. Throughout their lives, up to 70% of white women and more than 80% of women of African heritage are diagnosed with these tumors, also known as myomas, which mostly afflict women during their reproductive years. The delivery and expense of healthcare are significantly impacted by this disease on a global scale. Even though the majority of women with fibroids are asymptomatic, about 30% of them will require intervention due to significant symptoms that may include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, frequent urination, constipation, or infertility. Furthermore, poor obstetric outcomes have been linked to fibroids.
The current options for treating symptomatic fibroid include interventional radiology, medicinal, surgical, and expectant care. Surgery is still sometimes necessary, there is no doubt about that, but we must now determine whether using hormonal therapy and SPRMs enables less invasive surgery or even completely avoids surgery. The size, quantity, and position of the fibroids, as well as the gynecologist's experience and the technology that is available, all come into play when deciding between less invasive methods (uterus-sparing choices, like myomectomy). The majority of fibroids management techniques still involve surgical interventions, with hysterectomy, laparoscopic myomectomy, and hysteroscopic myomectomy being the most popular procedures.
For decades, the only procedure available to women who desired to keep their uterus was excision of the fibroids and anatomical restoration of the uterus, also during obstetrics. In between 80 and 90 percent of cases, myomectomy patients have symptom alleviation or symptom reduction. After surgery, the fibroids should not recur but, due to the growth of additional fibroids, up to 33% of women who undergo this surgery will require a second operation within 5 years. Depending on the quantity, size, and location of fibroids, this procedure can be performed in one of three ways. However, surgical options do not always solve the problems, especially in obstetrics.
In this Research Topic, we will try to dissect all the problems of fibroid surgery, both in gynecology and in obstetrics, criticizing many aspects of the topic that have not yet been fully clarified. We expect to receive, but not limited to: original articles, case reports and reviews on the topic of Fibroid Surgery Controversies in Obstetrics and Gynecology.